California-based Cradle, an artificial intelligence protein engineering company, has closed its Series B round of funding at $73m to bring innovation to biotech and support scientists worldwide.
AI platform for protein engineering, Cradle, has announced its Series B round of funding of $73M to take its total funding to over $100M. It was a Seed funding round led by IVP along and Index Ventures; Kindred Capital also joined the club. Further, this funding, too, will allow Cradle to build out these functions in its efforts to amplify its presence in the biotech industry.
AI-Driven Protein Engineering – Towards the Next Frontier:
Launched in February 2021 by Elise de Reus and Stef van Grieken, Cradle relies on generative AI to speed up protein design. Moreover, the platform allows scientists to design improved proteins exponentially faster up to 10x- A game changer for all sorts of industries, from the pharmaceutical to agricultural and sustainability industries.
Related Content: Biolevate Streamlines Medical Writing with AI, Strikes €6M Seed Round
To fuel its growth further, Cradle hopes to increase its staff and improve upon its current group of machine learning algorithms. The company has recently hired Sam Partovi as the Chief Commercial Officer to bolster its biotech division. Cradle builds its success with top talent from Google and Novartis driving its innovative efforts.
Cradle’s intelligent systems have provided profound advancements. For instance, a biotech customer doubled enzyme activity in 3 experimental rounds to cope with a stopped project. The company’s platform is currently in various commercial use across the food, pharma, and agriculture industries.
Future Vision for Cradle:
Cradle’s goal is to service a million scientists through its AI environment, to spur GF development of cures, green products, and biotechnology breakthroughs. Additionally, this next phase shall be funded by the Series B funding to enable Cradle to spread widely and deeply, across industries and geographies.
